Bocaliner™
Oral Mucosal Drug Delivery Device
A clinically validated, FDA-registered Class I medical device that dramatically extends mucosal contact time — unlocking superior outcomes across oncology, sublingual therapy, and beyond.
A Platform Device That Makes Every Oral Therapy Work Better
Bocaliner™ is a silicone oral mucosal liner worn in the mouth for 10–20 minutes after applying a topical medication or mouthwash. By holding the therapeutic agent in prolonged, direct contact with the oral mucosa, it dramatically improves absorption, reduces pain, and enhances clinical outcomes — without changing the drug itself.
Because it is drug-agnostic, Bocaliner™ can be paired with virtually any existing oral topical formulation, making it an ideal enhancement platform for pharma partners seeking to differentiate, extend, or reposition products.
- Extends mucosal drug-contact time well beyond standard rinse-and-spit protocols
- Covers parotid gland and submandibular gland ostia for broader mucosal coverage
- Made from medical-grade silicone — safe, flexible, easy to use
- Clinically tested in a Phase I/II randomized controlled trial (NCT05338398)
- Finished, manufacturable product — no additional R&D needed to commercialize
Two High-Growth Markets. One Platform Device.
Bocaliner™ sits at the convergence of the oncology supportive care market and the rapidly expanding oral transmucosal drug delivery sector — both among the fastest-growing segments in medtech/pharma.
Oral Mucositis — Oncology
40% of all chemotherapy patients develop oral mucositis — a debilitating, treatment-disrupting complication with limited solutions. Bocaliner™ is the only FDA-registered Class I device addressing this space, validated in published clinical research. North America leads with the largest regional share.
Oral Transmucosal Drug Delivery
The global oral transmucosal market is surging on demand for non-invasive, rapid-onset delivery — across pain management, CNS, cardiovascular, and addiction therapies. Bocaliner™ directly enhances drug dwell time and absorption for any sublingual or buccal formulation, making it a natural co-development partner.
Palliative, Rare Disease & Immunotherapy
Beyond oncology, Bocaliner™ has clear applicability in immunotherapy support, palliative oral care, rare disease applications requiring precise mucosal delivery, and pharma-sponsored clinical trials seeking a validated drug-delivery enhancement tool.
Proven in a Published Phase I/II Randomized Controlled Trial
Real-world oncology patients. Peer-reviewed findings. ClinicalTrials.gov registered (NCT05338398).
SPOM Trial — Key Details (NCT05338398)
Phase I/II randomized, double-arm controlled trial conducted at Yeolyan Hematology & Oncology Center, Yerevan, Armenia. Patients with hematologic malignancies undergoing active systemic chemotherapy.
What Sets Bocaliner™ Apart
A rare combination of regulatory clearance, clinical validation, and broad applicability — without requiring any changes to existing drug formulations.
Patented & FDA-Registered
US Patent 2022/0023022 A1 in force. FDA Class I, 510(k)-exempt device status removes the most significant regulatory barrier to market entry for a licensing partner.
Fully Drug-Agnostic
Works with any oral topical therapy — existing marketed drugs, new formulations, or investigational compounds. Partners can deploy it alongside their current product portfolio immediately.
Only FDA-Registered Device in Its Category
Among treatment options for chemotherapy-induced oral mucositis, Bocaliner™ stands as the only FDA-registered Class I device — a critical differentiator vs. rinses, gels, and biologics.
Finished, Scalable Product
No discovery-stage technology risk. The device is fully developed, manufacturable, and clinically tested — a licensing partner can accelerate directly to commercialization.
High Patient Acceptance
64% of patients in clinical trials said they would use it again. 75% reported good tolerability. Strong patient buy-in is a rare and commercially significant asset.
Global Market Access
Applicable across oncology, immunotherapy, palliative care, rare disease, and sublingual drug markets worldwide — with North America and Asia-Pacific representing the largest growth opportunities.
Patent & Regulatory Summary
Strong foundational IP protection with a clear, enforceable claim structure covering device design, method of use, and drug-delivery applications.
Patent Details
Key Patent Claims — Business Value
- Exclusive protection on the oral mucosal liner device design covering the palatal and buccal surfaces
- Method claims covering use of the device to extend drug contact time post-application
- Combination claims protecting device + topical drug application sequences
- Broad applicability across topical, sublingual, and mucosal drug classes — not limited to a single drug or indication
- Claim architecture supports both standalone device licensing and drug-device combination licensing structures
A Phased Campaign for Maximum Value & Partner Fit
Based on Bocaliner™'s IP profile, clinical validation stage, and market positioning, LCG recommends a three-phase outreach strategy targeting partners who can move quickly from licensing to commercialization.
Anchor the Oncology Position
- Target oncology supportive care divisions of mid-to-large pharma with existing OM treatment portfolios (e.g., Amgen, Mundipharma, Galera Therapeutics)
- Lead with the FDA-registered status and published Phase I/II data — the lowest-risk entry point in the category
- Offer exclusive licensing in the chemotherapy-induced OM indication as the primary anchor deal
- Position the device as a revenue-extending add-on to existing mouthwash, rinse, or mucosal gel product lines
Expand to the Drug Delivery Platform
- Approach sublingual/buccal drug delivery companies (pain management, CNS, cardiovascular, addiction) as the Phase II trial data matures
- Market Bocaliner™ as a validated co-development platform for enhancing bioavailability and improving clinical differentiation of existing drug pipelines
- Explore non-exclusive licensing structures across multiple therapeutic categories simultaneously
- Target pharmaceutical companies with sublingual films or buccal tablets who need to demonstrate enhanced efficacy vs. competing formulations
Pursue Co-Development & Global Expansion
- Leverage Phase II efficacy data to negotiate co-development deals with partners targeting rare diseases, immunotherapy support, and palliative care
- Approach Asia-Pacific partners specifically — the fastest-growing regional market for both oral mucositis treatment and oral transmucosal drug delivery
- Structure milestone-based royalty deals tied to new indication approvals to maximize long-term licensing value
- Explore strategic partnerships with medical device distributors for OTC/hospital supply channel access
⚡ Key Strategic Insight
The single most powerful licensing argument for Bocaliner™ is its combination of FDA-registered Class I status and published clinical data — this removes two of the highest-risk elements that slow licensing conversations. Partners can move directly to commercialization planning without regulatory uncertainty or unproven clinical claims.
Framing Bocaliner™ as a portfolio enhancer — not a standalone product competing against a partner's existing line — is the most effective positioning strategy. It extends the lifecycle and efficacy profile of existing drugs while adding a new revenue stream with minimal additional regulatory burden.
Explore Licensing Bocaliner™ Today
Licensing Consulting Group is accepting inquiries for exclusive, non-exclusive, and co-development licensing opportunities. Let's discuss how Bocaliner™ can strengthen your product portfolio.
🔒 Exclusive Licensing
Secure category exclusivity in defined therapeutic indications with full commercial rights
🤝 Non-Exclusive / R&D
Access the device for clinical research, pipeline development, and multi-indication use
🚀 Co-Development
Partner with E2Bio Life Sciences to jointly advance Phase II efficacy data and new indication studies